Leukemias, lymphomas, and other hematologic cancers
Drug Name
- “Another CAR in the Garage”: Q&A on CAR-T With UPenn’s Bruce Levine, PhD
- “Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy
- A Case of Intra-Abdominal Follicular Lymphoma Presenting as Heart Failure
- ADCETRIS
- Addition of Daratumumab to Frontline Treatment May Improve Outcomes in Transplant-Eligible Patients With Multiple Myeloma
- Addition of Investigational mAb Isatuximab May Represent a New Treatment Option in Multiple Myeloma
- After Long-Term Ibrutinib Therapy for CLL, BTK Mutations May Signal Progression
- Age at Diagnosis of Myeloproliferative Neoplasm Affects Pattern of Thrombotic Events but Not Mortality Risk
- ALIQOPA
- ALKERAN
- ALKERAN FOR INJECTION
- An Integrated Analysis for Selecting Ibrutinib-Based Combination Therapy in CLL
- Anti-CD19 CAR-T Therapy Shows Early Efficacy in ALL
- ARRANON
- ARZERRA
- ASCT Reduced the Risk of Early Relapse for Some Patients With Multiple Myeloma Receiving KRd
- BCMA CAR-T bb2121 Appears to Be Safe and Effective in Multiple Myeloma
- BELEODAQ
- BENDEKA
- BESPONSA
- BEXXAR
- BICNU
- Biological Differences Between 2 Rare Leukemias Do Not Influence Clinical Outcomes
- Bleomycin
- BLINCYTO
- BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
- BOSULIF
- BUSULFEX
- CALQUENCE
- CAMPATH
- CAR-T Cell Therapy Liso-Cel Deemed Safe and Active in CLL and SLL
- CAR-T in Multiple Myeloma: Promising Efficacy and Generally Manageable Toxicity
- Cardiovascular AEs Common With Carfilzomib in Multiple Myeloma
- Carfilzomib Dosing and Scheduling in Newly Diagnosed Multiple Myeloma
- CD33 and MPC-1: Monitoring Response to Bortezomib in Multiple Myeloma
- Cerebrovascular Disease: A Serious Complication After Allogeneic Hematopoietic Stem Cell Transplantation
- CERUBIDINE
- Changes in Hematologic Parameters Following Pesticide Exposure
- Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL
- Circulating EBV-CTLp as a Biomarker of Clinical Response to Tabelecleucel
- Cladribine
- Clinical Outcomes in Philadelphia-Negative ALL With Inotuzumab Ozogamicin Plus Chemotherapy
- CLL14 Phase 3 Trial: Venetoclax Combo as First-line Therapy
- CLOLAR
- clonoSEQ and MRD Testing in Multiple Myeloma and ALL
- Combination Regimen for Pretransplant Conditioning May Improve Outcomes for Patients With Multiple Myeloma
- Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
- Comparing Efficacy and Safety of Auto-HCT in Older and Younger Patients With Multiple Myeloma
- Consensus Panel on Maintenance Therapies Following Autologous Hematopoietic Cell Transplantation in Lymphoma
- Contrast-Enhanced MRI Characterization of Brain Cancers
- COPIKTRA
- Cure Rate Disparities Among Children With Burkitt Lymphoma
- Current and Prospective Therapies for Double-Hit Lymphoma
- Cyclophosphamide
- Cyclophosphamide Injection
- Cytarabine
- Cytogenetic Abnormalities Provide Prognostic Value in Predicting Acute Myeloid Leukemia Outcomes
- Dacarbazine
- DACOGEN
- Daratumumab Cuts Risk for Progression in Multiple Myeloma
- DARZALEX
- Darzalex Gets Approval for Additional Multiple Myeloma Indication
- Data Mining to Develop Mutation-Specific Treatments in Acute Myeloid Leukemia
- DAURISMO
- Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML
- DEPOCYT
- Depression at Time of Diagnosis May Worsen Survival in Blood Cancers
- Designing a Clinical Trial to Evaluate Multistage Treatment Approaches in CLL
- Direct-Acting Oral Anticoagulant Treatment for Acute Venous Thromboembolism
- Disease Progression Is Associated With Increased Costs for Patients With Hematologic Malignancies
- DOXIL
- Doxorubicin HCl
- Doxorubicin HCl Solution
- Early Study of PI3K Inhibitor Yields High Response Rate in R/R Follicular Lymphoma
- Early Treatment for Smoldering Multiple Myeloma
- EBV Reactivation After Transplant Associated With Worse Clinical Outcomes in Myelodysplastic Syndrome
- Effects of HLA Dimorphism on Clinical Outcomes of Immunotherapy in Acute Myeloid Leukemia
- Efficacy of 19-28z CAR-T in DLBCL Unclear: Phase 1 Study Readout
- ELZONRIS
- Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma
- EMPLICITI
- ERWINAZE
- Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
- EVOMELA
- Exploring Indications With Venetoclax
- Extranodal and Spleen Involvement Predict Outcomes in Follicular Lymphoma
- FARYDAK
- FDA Approves Novel Therapy for Relapsed, Refractory Multiple Myeloma
- FDA Panel Backs Pexidartinib for Rare Tumor, Votes Against Quizartinib for FLT3-ITD AML
- Five-Year Survival Less Than 40 Percent in Seniors With DLBCL
- Flow Cytometry as a Relapse Risk Assessment Tool in T-Cell Acute Lymphoblastic Leukemia
- Fludarabine
- Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia
- Follicular Lymphoma With Extranodal Disease Only: When to Suspect Systemic Disease
- FOLOTYN
- Gait Speed Effectively Predicts Clinical Outcomes in Older Patients With Hematologic Cancers
- GAZYVA
- GLEEVEC
- GLEOSTINE
- Greater Infection Risk With Unrelated Transplant Donors in Pediatric Acute Lymphoblastic Leukemia
- Heparin Derivative CX-01 May Boost Standard AML Induction
- High 5-Year OS Rate for Children and Young Adults with Relapsed/Refractory Hodgkin Lymphoma Receiving Moderate-Dose Salvage RT
- HIV-Induced Expression of PD-L1 on Regulatory B Cells May Promote AIDS-Related NHL
- HYDREA
- Ibrutinib Added to R-CHOP May Improve Outcomes for Patients Younger Than 60 Years
- Ibrutinib May Impair Natural Killer Cell Cytotoxic Activity, Study Suggests
- ICLUSIG
- IDAMYCIN PFS
- Idarubicin
- IDHIFA
- Imaging Studies Critical in Distinguishing Extramedullary Disease in Multiple Myeloma Diagnosis
- IMBRUVICA
- IMBRUVICA TABLETS
- Improved Long-Term Outcomes After Stronger Postinduction Intensification for Acute Lymphoblastic Leukemia
- Increased Risk for Second Malignancy After Multiple Lines of Treatment in Follicular Lymphoma
- Intensive Chemotherapy May Be Beneficial for Younger Patients With Myelodysplastic Syndrome
- Intravenous Busulfan Plus Melphalan vs Melphalan Alone as a Conditioning Regimen in Multiple Myeloma: Is There a Difference?
- INTRON A
- INTRON A SOLN
- ISTODAX
- JAKAFI
- KEYTRUDA
- KYMRIAH
- KYPROLIS
- Lack of Thromboprophylactic Benefit With Rivaroxaban in Ambulatory Patients With Cancer
- Late Relapse Rates After Immunochemotherapy Treatment for Diffuse Large B-Cell Lymphoma
- Lenalidomide Shown to Reduce the Risk of Progression in Smoldering Multiple Myeloma
- Less-Frequently Dosed Pegylated Asparaginase: Found as Safe and Effective as Standard Pegaspargase in Younger Patients With ALL
- LEUKERAN
- Likelihood of LVDD is Predictive of Carfilzomib-Induced Cardiovascular AEs in R/R Multiple Myeloma
- Long-Term Progression-Free Survival Is Strongest Factor in Cost Effectiveness of CAR-T Therapy for DLBCL
- Looking Back to Go Forward: CAR-T Cell Therapy in R/R CLL
- Low Response Rates to Hypomethylating Agents in Chronic Myelomonocytic Leukemia
- LUMOXITI
- Managing Neutropenic Sepsis in Patients With Cancer
- Marginal Zone Lymphoma Presentation at Multiple Mucosal Sites May Be Linked to Poorer Outcomes
- MARQIBO
- MATULANE
- Measuring Patient-Reported Outcomes in Waldenström Macroglobulinemia Patients Receiving Rituximab vs Ibrutinib-Rituximab
- MEK Inhibition Spurs Durable Responses in Patients With Histiocytic Neoplasms
- Mercaptopurine
- Methotrexate for injection
- Methotrexate injection
- Mitoxantrone HCl
- Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL
- Molecular Characterization of Pediatric Follicular Lymphoma
- Muscle Complaints Are a Frequent Side Effect of TKI Use in CML, but What Causes Them?
- MUSTARGEN
- Myeloma Trial Aims to Use Genetic Profile for Treatment Optimization
- MYLERAN
